ajanta pharma limited

Regd.Office: 'Ajanta House', Charkop, Kandivli (W), Mumbai-67

Statement of Financial Results for the quarter & year ended 31st March, 2013

₹ in Crores

	Particulars	Standalone Results					Consolidated Results	
		3 months ended			Accounting Year ended		Accounting Year ended	
		31/03/2013	31/12/2012	31/03/2012	31/03/2013	31/03/2012	31/03/2013	31/03/2012
		Unaudited			Audited		Audited	
1	**Income from Operations**							
	(a) Net sales (Net of excise duty)	**249.21**	**225.68**	**168.61**	**828.50**	**591.98**	**920.14**	**665.12**
	(b) Other operating income	0.23	3.66	7.49	10.70	12.29	10.70	12.28
	Total Income from Operations (net)	**249.44**	**229.34**	**176.10**	**839.20**	**604.27**	**930.84**	**677.40**
2	**Expenditure**							
	(a) Cost of materials consumed	99.36	79.95	78.01	284.09	230.29	286.32	232.51
	(b) Purchases of stock-in-trade	7.46	8.00	6.03	27.35	20.47	25.84	18.16
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(17.46)	(2.71)	(18.84)	(11.41)	(32.99)	(9.54)	(20.72)
	(d) Employee benefits expense	34.52	27.77	24.89	115.40	87.17	123.18	93.84
	(e) Depreciation and amortisation expense	8.98	8.06	8.24	32.70	30.68	34.17	31.87
	(f) Exchange rate difference (Net)	0.64	0.83	-	2.90	9.92	-	4.95
	(g) Other expenses	56.49	55.66	44.94	213.59	166.18	280.55	211.66
	Total expenses	**189.99**	**177.56**	**143.27**	**664.62**	**511.72**	**740.52**	**572.27**
3	**Profit from operations before other income, finance costs & tax (1-2)**	**59.45**	**51.78**	**32.83**	**174.58**	**92.55**	**190.32**	**105.13**
4	(a) Other Income	6.28	0.47	0.42	7.41	1.21	2.20	1.25
	(b) Exchange rate difference (Net)	-	-	2.06	-	-	3.40	-
5	**Profit from ordinary activities before finance costs & tax (3+4)**	**65.73**	**52.25**	**35.31**	**181.99**	**93.76**	**195.92**	**106.38**
6	Finance costs	5.35	3.37	4.06	18.48	14.01	19.13	15.43
7	**Profit from ordinary activities before tax (5-6)**	**60.38**	**48.88**	**31.25**	**163.51**	**79.75**	**176.79**	**90.95**
8	Tax Expense	33.29	16.31	7.65	62.39	13.26	64.68	13.69
9	**Net Profit for the period (7-8)**	**27.09**	**32.57**	**23.60**	**101.12**	**66.49**	**112.11**	**77.26**
10	Minority Interest	NA	NA	NA	NA	NA	Nil	Nil
11	**Net Profit for the period after minority interest (9-10)**	**27.09**	**32.57**	**23.60**	**101.12**	**66.49**	**112.11**	**77.26**
12	Paid-up Equity Share Capital	11.80	11.80	11.80	11.80	11.80	11.80	11.80
	Face value of Equity Share - in ₹	5	5	10	5	10	5	10
13	Reserve excluding Revaluation Reserves	NA	NA	NA	344.48	260.04	381.63	286.23
14	Earnings Per Share - not annualised (refer note 4)							
	(a) Basic - in ₹	11.56	13.91	10.08	43.17	28.39	47.87	32.99
	(b) Diluted - in ₹	11.53	13.88	10.05	43.07	28.33	47.76	32.92
A	PARTICULARS OF SHAREHOLDING							
1	Public Shareholding							
	- Number of shares	6,321,498	6,392,040	3,497,230	6,321,498	3,497,230	6,321,498	3,497,230
	- Percentage of shareholding	27.00%	27.30%	29.87%	27.00%	29.87%	27.00%	29.87%
2	Promoters and promoter group shareholding							
	a) Pledged/Encumbered							
	- Number of shares	1,100,000	1,100,000	550,000	1,100,000	550,000	1,100,000	550,000
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	6.43%	6.46%	6.70%	6.43%	6.70%	6.43%	6.70%
	- Percentage of shares (as a % of the total share capital of the company)	4.70%	4.70%	4.70%	4.70%	4.70%	4.70%	4.70%
	b) Non-encumbered							
	- Number of shares	15,995,502	15,924,960	7,661,270	15,995,502	7,661,270	15,995,502	7,661,270
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	93.57%	93.54%	93.30%	93.57%	93.30%	93.57%	93.30%
	- Percentage of shares (as a % of the total share capital of the company)	68.30%	68.00%	65.43%	68.30%	65.43%	68.30%	65.43%
B	INVESTOR COMPLAINTS						3 months ended 31/03/2013	
	Pending at the beginning of the quarter and remaining unresolved at the end of the quarter						Nil	
	Received and disposed off during the quarter						19	

AJANTA PHARMA LIMITED MUMBAI

₹ in Crores

	Audited Statement of Assets & Liabilities	Standalone		Consolidated	
	Particulars as at	31/03/2013	31/03/2012	31/03/2013	31/03/2012
A	EQUITY AND LIABILITIES				
1	Shareholders' funds				
	(a) Share Capital	11.80	11.80	11.80	11.80
	(b) Reserves and Surplus	344.48	260.04	381.63	286.23
	Sub-total - Shareholders' funds	356.28	271.84	393.43	298.03
2	Non-current liabilities				
	(a) Long-term borrowings	72.20	75.36	73.33	76.09
	(b) Deferred tax liabilities (net)	23.65	17.09	23.65	17.09
	(c) Other long-term liabilities	2.50	2.50	2.50	2.50
	(d) Long-term provisions	2.98	4.91	2.98	4.91
	Sub-total - Non-current liabilities	101.33	99.86	102.46	100.59
3	Current liabilities				
	(a) Short-term borrowings	51.26	86.87	51.26	95.27
	(b) Trade payables	130.04	105.92	131.71	101.32
	(c) Other current liabilities	16.81	42.22	19.44	43.15
	(d) Short-term provisions	19.66	10.45	19.92	10.45
	Sub-total - Current liabilities	217.77	245.46	222.33	250.19
	TOTAL - EQUITY AND LIABILITIES	675.38	617.16	718.22	648.81
B	ASSETS				
1	Non- current assets				
	(a) Fixed assets	275.22	239.08	285.05	248.64
	(b) Non-current investments	18.86	17.05	8.46	8.47
	(c) Long-term loans and advances	48.41	50.56	48.61	50.75
	(d) Other non-current assets	7.09	1.28	7.09	1.28
	Sub-total - Non-current assets	349.58	307.97	349.21	309.14
2	Current assets				
	(a) Inventories	143.51	162.35	147.60	167.80
	(b) Trade receivables	135.19	125.42	150.47	141.00
	(c) Cash and cash equivalents	25.11	5.08	46.23	11.47
	(d) Short-term loans and advances	21.32	15.61	24.04	18.67
	(e) Other current assets	0.67	0.73	0.67	0.73
	Sub-total - Current assets	325.80	309.19	369.01	339.67
	TOTAL - ASSETS	675.38	617.16	718.22	648.81

Notes :

1 Above results have been reviewed by Audit Committee and approved by Board of Directors at their meeting held on 30th April, 2013.

2 Board of Directors have recommended dividend of ₹6.25 per equity share, on face value of ₹5 per share, for the year ended 31st March, 2013.

3 Tax expenses for current quarter and financial year includes one time expense of ₹15.75 Crs arising due to filing of revised returns for earlier years.

4 Earning per share has been disclosed considering increased number of shares post sub division, for all periods reported herein above.

5 Figures pertaining to last quarter are balancing figures between audited figures in respect of full financial year and published year to date figure upto the end of third quarter of relevant financial year.

6 The company has one segment of activity namely, pharmaceuticals.

7 Consolidated financial results includes financial results of the company and its wholly owned subsidiaries prepared in accordance with AS 21.

8 Previous period's figures have been regrouped wherever necessary.

AJANTA PHARMA LIMITED MUMBAI

By order of the Board
For Ajanta Pharma Ltd.

Yogesh M. Agrawal
Managing Director

Mumbai, 30th April, 2013